Literature DB >> 4076253

Chronopharmacology of hydrocortisone and 9 alpha-fluorhydrocortisone in the treatment for congenital adrenal hyperplasia.

H Moeller.   

Abstract

The conventional treatment of CAH with hydrocortisone (16-19 mg/m2 per day) and 9 alpha-F-cortisol (just enough to normalise renin concentrations, started at 07:00 h) was ineffective in suppressing the early morning rise of 17-OH-progesterone and in turn androgens in about 20% of our patients. The present work explored the effect of a modified dosage regimen of the drug in five patients. The schedule was: 03:00 h F 33% + 9 alpha-F-F 33%; 07:00 h F 30%; 12:00 h F 22% + 9 alpha-F-F 33%; 17:30 h F 15% + 9 alpha-F-F 33%. Monitored levels of circulating 17-OH-progesterone, testosterone, and individual urinary 17-ketosteroids showed significant improvement, which was not achieved by giving higher or later evening doses. Menarche was induced in two girls (bone age 15 years). The modified dosage schedule offers on the one hand the possibility of better management of CAH, and on the other, cuts down the risk of enhanced Cushing-like effects, which in animal models have been related frequently to dosage schedules not corresponding to the circadian rhythm. The difficulty of administering the drugs at 03:00 h should be overcome by the development of a late-releasing preparation.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4076253     DOI: 10.1007/BF00441780

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  4 in total

1.  The effect of different treatment regimens on hormonal profiles in congenital adrenal hyperplasia.

Authors:  R Smith; R A Donald; E A Espiner; C Glatthaar; G Abbott; M Scandrett
Journal:  J Clin Endocrinol Metab       Date:  1980-08       Impact factor: 5.958

2.  A longitudinal study of steroid excretion patterns in children during adolescent growth.

Authors:  D Gupta
Journal:  Steroidologia       Date:  1970

3.  Effect of hydrocortisone dose schedule on adrenal steroid secretion in congenital adrenal hyperplasia.

Authors:  J Winterer; G P Chrousos; D L Loriaux; G B Cutler
Journal:  J Pediatr       Date:  1985-01       Impact factor: 4.406

4.  [Andrenogenital syndrome (author's transl)].

Authors:  E Nieschlag; H Wenner; H Breu; E J Wickings; G Schellong
Journal:  Dtsch Med Wochenschr       Date:  1980-04-25       Impact factor: 0.628

  4 in total
  6 in total

Review 1.  Therapeutic drug monitoring in the neonate and paediatric age group. Problems and clinical pharmacokinetic implications.

Authors:  J T Gilman
Journal:  Clin Pharmacokinet       Date:  1990-07       Impact factor: 6.447

2.  Towards the tailoring of glucocorticoid replacement in adrenal insufficiency: the Italian Society of Endocrinology Expert Opinion.

Authors:  A M Isidori; G Arnaldi; M Boscaro; A Falorni; C Giordano; R Giordano; R Pivonello; C Pozza; E Sbardella; C Simeoli; C Scaroni; A Lenzi
Journal:  J Endocrinol Invest       Date:  2019-11-26       Impact factor: 4.256

3.  Replication of cortisol circadian rhythm: new advances in hydrocortisone replacement therapy.

Authors:  Sharon Chan; Miguel Debono
Journal:  Ther Adv Endocrinol Metab       Date:  2010-06       Impact factor: 3.565

4.  Nocturnal Dexamethasone versus Hydrocortisone for the Treatment of Children with Congenital Adrenal Hyperplasia.

Authors:  Andrew Dauber; Henry A Feldman; Joseph A Majzoub
Journal:  Int J Pediatr Endocrinol       Date:  2010-09-14

5.  A pharmacokinetic and pharmacodynamic study of delayed- and extended-release hydrocortisone (Chronocort) vs. conventional hydrocortisone (Cortef) in the treatment of congenital adrenal hyperplasia.

Authors:  Somya Verma; Carol Vanryzin; Ninet Sinaii; Mimi S Kim; Lynnette K Nieman; Shayna Ravindran; Karim A Calis; Wiebke Arlt; Richard J Ross; Deborah P Merke
Journal:  Clin Endocrinol (Oxf)       Date:  2009-05-25       Impact factor: 3.478

6.  An oral multiparticulate, modified-release, hydrocortisone replacement therapy that provides physiological cortisol exposure.

Authors:  Martin Whitaker; Miguel Debono; Hiep Huatan; Deborah Merke; Wiebke Arlt; Richard J Ross
Journal:  Clin Endocrinol (Oxf)       Date:  2013-09-20       Impact factor: 3.478

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.